Tenderwize
Retour à la recherche

Supply of pharmaceutical products for compassionate and early access use

31 CHU·Toulouse, France·EUR 450M·Deadline Apr 02, 2034 · 2734 days left·Restricted·Supplies·DPS
Inscrivez-vous pour sauvegarderOpen documents
High valueStructured notice only
Titre original de l'avis

France – Pharmaceutical products – FOURNITURE DE MEDICAMENTS en accès compassionnels et en accès précoces (ex-ATU)

65/100

Score d'opportunité

Needs reviewHigh complexity
SuppliesDPSOpen
Pourquoi ce score ?

Opportunité

65 / 100

Complexité

70 / 100

Facteurs de risque

Since the DPS has been running since 2017, many operators are already admitted, leading to intense competition in mini-...

DPS does not guarantee any contracts; each specific contract is awarded via separate mini-competitions. Estimated value...

Restricted procedure — pre-qualification required

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
31 CHU
Pays
France
CPV
33600000 - Pharmaceutical products
Date limite
Apr 02, 2034
Valeur estimée
EUR 450M

Aperçu

Moderate opportunity

Faits clés

  • EUR 450M estimated value
  • Dynamic Purchasing System (DPS)
  • Supplies contract
  • 1 lot
  • Duration until Apr 2034
  • Supply of pharmaceutical products under compassionate access and early access (ex-ATU) authorizations.
  • DPS covers all product categories (no breakdown).
Afficher le résumé complet

This notice is a corrigendum extending a Dynamic Purchasing System (DPS) for the supply of pharmaceutical products for compassionate and early access use (ex-ATU) in France. The DPS, managed by CHU de Toulouse on behalf of the UniHA group, was originally established in 2017 and is now extended by 120 months (until April 2034). Estimated annual value is €450 million (€1.8 billion total over 10 years). The DPS is open to new operators, but existing participants are automatically retained. No procurement documents were analyzed, and key details (eligibility, award criteria) are missing from the provided data.

Risques

Since the DPS has been running since 2017, many operators are already admitted, leading to intense competition in mini-...

DPS does not guarantee any contracts; each specific contract is awarded via separate mini-competitions. Estimated value...

Restricted procedure — pre-qualification required

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Operators already admitted in the original DPS are automatically retained and do not need to reapply.

Administrative

  • New operators must submit an application via the e-procurement platform (www.marches-publics.gouv.fr).
  • All submissions must be made electronically.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Toulouse, FRA

Profil acheteur

Ouvrir le profil

Identifiant

26310012500016

Activité

Health

Lots (1)

LOT-0001

Supply of pharmaceutical products for compassionate and early access use

Single lot covering all pharmaceutical products for compassionate and early access (ex-ATU). The DPS is not divided into product categories. Estimated annual value: €450 million (HT). Total estimated value over 10 years: €1.8 billion.

SuppliesDPSEU fundedElectronic submission

EUR 450M

Valeur estimée

Durée

Apr 2024 - Apr 2034

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 02, 2034

Détails de la procédure

Date de publication
01 Feb 2024
Langues
French

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
66960-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30